Trial Profile
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Luxeptinib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man
- Sponsors Aptose Biosciences
- 14 Dec 2023 Planned End Date changed from 1 Mar 2024 to 1 Dec 2024.
- 14 Dec 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Feb 2024.
- 20 Jun 2023 Planned End Date changed from 1 May 2024 to 1 Mar 2024.